Clinical trial
Vorinostat in Treating Patients With Acute Myeloid Leukemia
NCT00305773 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00305773 |
|---|---|
| Title | Vorinostat in Treating Patients With Acute Myeloid Leukemia |
| Official title | A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Acute Myeloid Leukemia (AML) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13, q22) and 13 more |
| Intervention type | Drug |
| Interventions | vorinostat |
| Enrollment | 37 |
| Start date | Jan 1, 2006 |
| Primary completion | May 1, 2009 |
| Completion | Jan 1, 2010 |
| First posted | Mar 22, 2006 |
| Last update posted | May 19, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: